Leerink Partnrs Predicts Increased Earnings for AC Immune

AC Immune SA (NASDAQ:ACIU - Free Report) - Leerink Partnrs increased their FY2024 EPS estimates for shares of AC Immune in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($0.57) per share for the year, up from their prior estimate of ($0.60). The consensus estimate for AC Immune's current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for AC Immune's Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.83) EPS and FY2026 earnings at ($0.55) EPS.

Separately, HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of AC Immune in a report on Friday, November 15th.

AC Immune Stock Up 0.9 %

Shares of ACIU traded up $0.03 during midday trading on Friday, reaching $2.73. 133,432 shares of the stock were exchanged, compared to its average volume of 144,319. The stock's 50 day simple moving average is $2.86 and its 200 day simple moving average is $3.17. AC Immune has a twelve month low of $2.25 and a twelve month high of $4.98. The company has a market cap of $269.61 million, a P/E ratio of -5.92 and a beta of 1.30.

Institutional Investors Weigh In On AC Immune

Large investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new stake in AC Immune in the second quarter valued at about $218,000. China Universal Asset Management Co. Ltd. lifted its stake in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company's stock valued at $72,000 after purchasing an additional 7,400 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in AC Immune by 6.4% in the third quarter. Geode Capital Management LLC now owns 58,296 shares of the company's stock valued at $220,000 after buying an additional 3,499 shares in the last quarter. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.